Researchers at the New York University School of Medicine (NY, USA) may have found a way to treat latent Kaposi\'s sarcoma-associated herpesvirus (KSHV, also known as HHV8) infections. Ornella Flore and colleagues report that glycyrrhizic acid (GA)---a compound isolated from liquorice that inhibits the lytic replication of other herpesviruses---terminates KSHV latent infection of B lymphocytes (*J Clin Invest* 2005; **115:** 642--52). "This is the first time we have found anything that targets latent gene expression in herpesvirus-infected cells", says Flore, "but it is too soon to say whether GA will be effective against other latent herpesviruses or suitable for clinical use against KSHV".

The treatment of infections caused by herpesvirus is complicated by their ability to establish latent infections. Herpesviruses can hide within their host cells, making only the few proteins needed to maintain latency, and emerges at a later date to cause overt disease. No currently available drugs directly attack latent herpesviruses, although latent Epstein--Barr virus can be reactivated, thus allowing treatment with standard antiviral drugs.

Flore\'s team reports that GA disrupts latent KSHV infection of B lymphocytes in culture by downregulating the expression of latency-associated nuclear antigen and upregulating viral cyclin expression, resulting in the selective death of KSHV-infected cells. The next step, explains Flore, "is to see whether GA can inhibit the growth of KSHV-induced human tumours transplanted into mice. GA is already used clinically in Japan to treat hepatitis, so this lead is definitely worth following."

"GA is the first antiviral to have an effect on latently KSHV-infected lymphoma cells", says KSHV expert Ethel Cesarman (Weill Medical College of Cornell University, New York, USA). But, she notes, "we don\'t know yet the sites of KSHV infection in immunocompetent individuals and which (if any) viral genes are expressed, so it is difficult to predict whether GA might clear KSHV completely from the body".

Jindrich Cinatl (University Hospital Medical School, Frankfurt, Germany), who is studying GA treatment of severe acute respiratory syndrome, also finds Flore\'s results intriguing. However, he warns that the GA concentrations needed to terminate latent KSHV infection in B lymphocytes are higher than those used to treat hepatitis and may cause unacceptable side-effects. Therefore, chemical modification of GA might be required before it can be used to treat latent herpesvirus infections.
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